Russ Conroy

1 day ago | cancernetwork.com | Russ Conroy

Administering tislelizumab-jsgr (Tevimbra) as monotherapy or in combination with other agents significantly prolonged progression-free survival (PFS) and overall survival (OS) across different lung cancer populations, according to findings from a systematic review and meta-analysis published in Cureus.1Across 4 phase 3 studies, treatment with tislelizumab significantly improved OS vs control therapy, with no heterogeneity noted across trials (HR, 0.72; 95% CI, 0.63-0.81).

1 day ago | cancernetwork.com | Russ Conroy

Tumor treating fields (TTFields; Optune Lua) in combination with immune checkpoint inhibitors (ICIs) or docetaxel has received the Conformité Européenne (CE) Mark approval as a therapy for patients with metastatic non–small cell lung cancer (NSCLC) who have progressed on or after a platinum-containing regimen, according to a press release from the developers, Novocure.1 Developers have launched the local registration requirements for TTFields in Germany and are anticipating that the therapy...

2 days ago | cancernetwork.com | Russ Conroy

Treatment with nadofaragene firadenovec-vncg (Adstiladrin) elicited a strong complete responses (CR) rate in a small cohort of patients with high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors, according to a press release on findings from a Japanese phase 3 trial.1 Findings presented at the 112th Annual Meeting of the Japanese Urological Association demonstrated a CR rate of 75% (n =...

3 days ago | cancernetwork.com | Russ Conroy

The number of prior lines of therapy did not influence how patients with multiple myeloma locally responded to radiotherapy, according to findings from a retrospective study published in Advances in Radiation Oncology.1Six-month local responses were evaluable for 217 lesions; 13.4% (n = 29) showed complete responses (CRs), 65% (n = 141) showed partial responses (PRs), 19.4% (n = 42) exhibited stable disease, and 2.3% (n = 5) demonstrated progressive disease.

4 days ago | cancernetwork.com | Russ Conroy

Hyper-fractionated twice-daily radiotherapy conferred an overall survival (OS) improvement vs standard-dose radiation without increasing toxicity among patients with limited-stage small cell lung cancer (LS-SCLC), according to findings from a phase 3 study (NCT03214003) published in Lancet Respiratory Medicine.1 After a median follow-up of 46 months (IQR, 33-56) across the entire study population, the median OS was 60.7 months (95% CI, 49.2-62.0) with 54 Gy of radiation vs 39.5 months (95%...